恒瑞医药子公司注射用SHR—A2009获药物临床试验批准

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, an antibody-drug conjugate targeting HER3, aimed at treating advanced solid tumors [1] Group 1 - The clinical trial will focus on the safety, tolerability, and efficacy of SHR-A2009 in combination with anti-tumor therapy in patients with advanced solid tumors [1] - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, leading to internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1]